VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
CHRN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
CHRNChronoScale Corporation
$9.39$38M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksCHRNBalance Sheet

ChronoScale Corporation (CHRN) Balance Sheet

13Y historyFree accessUpdated daily

The company's financial foundation is rapidly eroding, with total assets contracting to $19.7 million in 2026Q1 while the debt-to-equity ratio has climbed to 0.75.

Income StatementBalance SheetCash FlowRatios

CHRN Balance Sheet

Annual statement

CHRN Balance Sheet

ChronoScale Corporation (CHRN) balance sheet — 13-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Total Current Assets30.69M14.05M18.84M20.21M31.04M47.8M18.42M18.81M14.97M34.94M20.68M25.2M29.3M29.18K
Cash & Short-Term Investments15.22M1.17M6.49M8.64M20.52M40.41M12.86M10.87M7.66M27.81M16.85M19.55M25.19M29.18K
Cash Only15.22M1.17M6.49M8.64M20.52M40.41M12.86M10.87M7.66M27.81M16.85M19.55M25.19M29.18K
Short-Term Investments00000000000000
Accounts Receivable7.56M7.31M7.24M5.64M4.63M4.66M3.39M5.21M3.66M2.76M1.78M2.07M1.55M549K
Days Sales Outstanding200.81208.41147.38112.72130.74151.31139.27136.59117.89137.0145.6987.19106.1460.69
Inventory04.82M4.57M5.05M5.19M2.24M1.98M2.49M3.37M3.02M1.56M1.06M622K725K
Days Inventory Outstanding26.54295.6198.29200.35282.66181.97189.39127.01175.2208.9650.3851.5260.2597.47
Other Current Assets4.99M750K541K875K700K0191K238K281K1.34M502K2.09M1.55M1.12M
Total Non-Current Assets264.71M6.06M7.81M8.71M9.87M1.37M2.18M3.11M2.69M3.05M3.74M7M4.17M3.38M
Property, Plant & Equipment209.66M1.82M2.37M3M3.99M1.21M1.86M2.74M2.37M2.25M2.44M2.63M2.1M1.57M
Fixed Asset Turnover0.22x7.03x7.58x6.10x3.24x9.32x4.78x5.08x4.79x3.27x5.84x3.30x2.53x2.10x
Goodwill54.39M431K431K431K431K00189K189K189K189K189K00
Intangible Assets03.5M4.58M4.89M5.22M0000491K1.03M1.58M55K0
Long-Term Investments000000036K000000
Other Non-Current Assets664K311K433K392K231K164K320K142K134K122K91K2.6M2.02M1.81M
Total Assets295.4M20.11M26.65M28.92M40.9M49.17M20.6M21.91M17.66M37.99M24.43M32.2M33.47M29.18K
Asset Turnover0.13x0.64x0.67x0.63x0.32x0.23x0.43x0.64x0.64x0.19x0.58x0.27x0.16x113.18x
Asset Growth %-78.37%-24.54%-7.84%-29.3%-16.81%138.7%-6.01%24.13%-53.52%55.53%-24.14%-3.81%114635.22%-
Total Current Liabilities101.17M8.64M7.54M8.12M9.2M6.86M4.97M7.83M10.13M9.16M6.31M8.62M6.61M14.12K
Accounts Payable15.78M1.43M1.55M1.85M3.15M3.11M1.5M1.9M3.16M2.42M1.88M2.69M783K1.5M
Days Payables Outstanding38.4187.7367.3373.28171.71252.18143.7297.11164.02167.1660.83131.4275.85201.48
Short-Term Debt10.54M3.26M1.25M1.25M2.31M229K548K2.77M2.33M2.14M54K80K41K9.32K
Deferred Revenue (Current)5.07M1.73M1.96M1.99M1.12M1.22M1.5M1.49M1.1M1.1M825K3.96M3.41M-1.5M
Other Current Liabilities4.99M00606K0284K235K567K1.06M1.24M2.31M682K490K4.8K
Current Ratio0.30x1.63x2.50x2.49x3.37x6.97x3.70x2.40x1.48x3.81x3.28x2.92x4.43x2.07x
Quick Ratio0.30x1.07x1.89x1.87x2.81x6.65x3.31x2.08x1.14x3.48x3.03x2.80x4.34x-49.27x
Cash Conversion Cycle188.93416.29278.35239.8241.6981.1184.94166.49129.06178.835.237.2990.54-43.33
Total Non-Current Liabilities43.58M2.45M6.41M8.2M6.26M5.09M11.19M7.29M4.79M7.43M11.58M14.77M4.06M9.32K
Long-Term Debt151K798K3.85M4.83M3.77M1.99M3.08M407K2.65M4.83M6.79M077K867K
Capital Lease Obligations38.4M147K452K723K1.09M0233K711K000000
Deferred Tax Liabilities00000000585K1.65M3.55M-21K00
Other Non-Current Liabilities5.43M89K182K471K374K1.62M6.08M4.38M652K1.79M3.99M10.16M1.97M-857.68K
Total Liabilities144.75M11.08M13.95M16.31M15.46M11.95M16.16M15.12M14.93M16.6M17.89M23.39M10.67M14.12K
Total Debt111.06M4.64M5.98M7.17M7.5M2.22M3.86M3.89M4.98M7M6.84M80K118K9.32K
Net Debt95.84M3.48M-510K-1.47M-13.02M-38.18M-9.01M-6.98M-2.67M-20.81M-10M-19.47M-25.07M-19.85K
Debt / Equity0.74x0.51x0.47x0.57x0.29x0.06x0.87x0.57x1.83x0.33x1.05x0.01x0.01x0.62x
Debt / EBITDA-8.02x-------------
Net Debt / EBITDA-6.92x-------------
Interest Coverage-17.00x-36.85x-41.12x-49.32x-95.67x-85.41x-112.85x-30.59x-43.99x-43.94x-1465.88x-1505.92x-76.63x-
Total Equity150.65M9.03M12.71M12.61M25.44M37.22M4.43M6.8M2.73M21.39M6.53M8.81M22.8M15.05K
Equity Growth %-118.64%-28.96%0.8%-50.45%-31.64%739.4%-34.77%149.16%-87.25%227.53%-25.85%-61.37%151384.95%-
Book Value per Share1.043.729.4513.6429.4445.509.2821.2710.02135.1681.07135.69458.840.30
Total Shareholders' Equity150.65M9.03M12.71M12.61M25.44M37.22M4.43M6.8M2.73M21.39M6.53M8.81M22.8M15.05K
Common Stock145K37K22K15K13K13K8K87K63K60K22K105K102K6.35K
Retained Earnings-241.95M-262.4M-250.47M-239.15M-223.95M-208.87M-199.1M-183.28M-171.15M-144.15M-114.86M-91.39M-71.8M-16.95K
Treasury Stock00000000000000
Accumulated OCI0-692K957K156K563K-17K-847K50K-92K-340K79K-1K-33.47M-27.61M
Minority Interest00000000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Imminent liquidity and solvency

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Rapid Erosion of Financial Foundation

As reported in recent financial filings, Ekso Bionics' total assets have contracted from $28.9 million in 2023Q4 to $19.7 million in 2026Q1, reflecting a persistent decline in the company's resource base that signals a weakening business trajectory and an inability to sustain its current operational scale.

The consistent reduction in total assets, coupled with a steady accumulation of deficit in retained earnings, suggests that the company is consuming its capital base to fund ongoing operating losses. This trend indicates that the business model has yet to achieve the necessary scale to stabilize its balance sheet, leaving it increasingly exposed to external financing requirements.

Critical Depletion of Cash Reserves

Based on the company's reported figures, cash reserves plummeted to $1.2 million by 2025Q4, representing a severe liquidity contraction from the $8.6 million held in 2023Q4, which leaves the firm with a dangerously thin buffer against its ongoing operational burn and potential unforeseen capital requirements.

The rapid decline in cash, despite a current ratio of 1.55, suggests that the company's liquidity is largely tied up in less liquid assets or is being rapidly exhausted by operating cash outflows. Investors should monitor this closely, as the current cash position appears insufficient to support long-term operations without immediate and potentially dilutive capital raises.

Leverage Dynamics Amidst Capital Constraints

According to recent balance sheet data, Ekso's debt-to-equity ratio has fluctuated significantly, reaching 0.75 in 2026Q1, which indicates that the company is increasingly relying on debt financing to bridge the gap created by its inability to generate sufficient internal cash flow from its core medical device operations.

While the absolute debt levels appear manageable in isolation, the rising D/E ratio in the context of declining equity and negative profitability suggests that debt is being used as a survival mechanism rather than a strategic growth tool. This reliance on leverage in a distressed state may limit future financing flexibility and increase the cost of capital.

Deferred Revenue Signals Stagnant Pipeline

As indicated in financial statements, deferred revenue has declined from $4.2 million in 2023Q4 to $2.8 million in 2026Q1, suggesting a contraction in the company's long-term service contract pipeline and a potential slowdown in future recurring revenue streams that are vital for long-term stability.

The downward trend in deferred revenue may imply that the company is struggling to secure new service agreements or that existing contracts are not being renewed at previous rates. This lack of visibility into future performance exacerbates the risks associated with the company's lumpy, capital-expenditure-dependent sales model.

Accumulated Deficit Masks Structural Fragility

Based on reported figures, the company's retained earnings deficit has deepened to -$269.3 million as of 2026Q1, a staggering figure that highlights the long-term failure of the current business model to convert R&D investment into sustainable, profitable growth for shareholders over the past several years.

This massive accumulated deficit serves as a stark reminder of the capital intensity required to develop and commercialize robotic medical devices, suggesting that the company's historical investments have not yet yielded a competitive return. The persistence of this deficit warrants further investigation into whether the current technology platform can ever achieve the margins necessary to reverse this trend.

CHRN — Frequently Asked Questions

Quick answers to the most common questions about buying CHRN stock.

What are the total assets of ChronoScale Corporation (CHRN)?

As of 2025, ChronoScale Corporation (CHRN) had total assets of $20.1M including $14.0M in current assets.

How much debt does ChronoScale Corporation (CHRN) have?

ChronoScale Corporation (CHRN) carries total debt of $4.6M, offset by $1.2M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of ChronoScale Corporation?

ChronoScale Corporation (CHRN) has total shareholders' equity (book value) of $9.0M ($3.72 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is ChronoScale Corporation's current ratio and liquidity?

ChronoScale Corporation (CHRN) reported a current ratio of 1.63x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.